Literature DB >> 19039754

Symptomatic tachy- and bradyarrhythmias after transcatheter closure of interatrial communications with Amplatzer devices.

Małgorzata Szkutnik1, Anna Lenarczyk, Jacek Kusa, Jacek Białkowski.   

Abstract

BACKGROUND: The aim of this paper is to present our own experience related to frequency of symptomatic tachy- and bradyarrhythmias in patients after transcatheter closure of interatrial defects (ASD) and patent foramen ovale (PFO) using Amplatzer plugs.
METHODS: Transcatheter closure of interatrial communications with Amplatzer devices was carried out on 739 patients in our center. Only patients with new symptomatic arrhythmias (who required pharmacotherapy, cardioversion or pacemaker implantation) were included in to the study. All patients who had had arrhythmias prior to ASD closure, such as supraventricular tachycardias (SVT) or atrial flutter/fibrillation (AF), were excluded.
RESULTS: New tachy- and bradyarrhythmias after implantation of Amplatzer devices were observed in 11 patients (1.5%). There were 9 patients (mean age 36.7 years) with atrial tachyarrhythmias (AF in 8 and SVT in 1 patients), which occurred between the first day and 3 months after implantation. Seven patients were treated initially by pharmacotherapy; in 2 of them sinus rhythm returned just after cardioversion. In other 2 patients cardioversion was performed as an initial therapy. In none of these patients, but one recurrence of tachycardia was observed; however, 7 of them had pharmacotherapy prolonged up to 1 year. In 2 patients, aged 15 and 16, complete atrioventricular (AV) block was observed 4.3 and 1.5 years after Amplatzer implantation, respectively. In the first patient intermittent second-degree AV block (Mobitz II) was observed before ASD closure. In both patients, a DDDR pacemaker was implanted.
CONCLUSIONS: Transcatheter closure of ASD using Amplatzer devices is associated with a risk of new atrial tachyarrhythmias (usually early after the procedure and in older patients). The risk of conduction disturbances such as complete heart block, which can occur in late followup, is low. Thence, close long-term follow-up of these patients is obligatory.

Entities:  

Mesh:

Year:  2008        PMID: 19039754

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  5 in total

1.  Benefit of atrial septal defect closure in adults: impact of age.

Authors:  Michael Humenberger; Raphael Rosenhek; Harald Gabriel; Florian Rader; Maria Heger; Ursula Klaar; Thomas Binder; Peter Probst; Georg Heinze; Gerald Maurer; Helmut Baumgartner
Journal:  Eur Heart J       Date:  2010-10-12       Impact factor: 29.983

2.  Holter electrocardiography findings and P-wave dispersion in pediatric patients with transcatheter closure of atrial septal defects.

Authors:  Isa Ozyilmaz; Sinem Ozyilmaz; Hasan Tahsin Tola; Murat Saygi; Neslihan Kiplapinar; Cansaran Tanıdır; Yakup Ergul; Alper Guzeltas; Ender Odemis
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-10-08       Impact factor: 1.468

3.  Transcatheter closure of atrial septal defects in children, middle-aged adults, and older adults: failure rates, early complications; and balloon sizing effects.

Authors:  Chodchanok Vijarnsorn; Kritvikrom Durongpisitkul; Prakul Chanthong; Paweena Chungsomprasong; Jarupim Soongswang; Duangmanee Loahaprasitiporn; Apichart Nana
Journal:  Cardiol Res Pract       Date:  2012-06-19       Impact factor: 1.866

4.  Comparison of Transcatheter Atrial Septal Defect Closure in Children, Adolescents and adults: Differences, Challenges and Short-, Mid- and Long-Term Results.

Authors:  Turkay Saritas; Ilker Kemal Yucel; Ibrahim Halil Demir; Fadli Demir; Abdullah Erdem; Ahmet Celebi
Journal:  Korean Circ J       Date:  2016-10-20       Impact factor: 3.243

5.  Late complete atrioventricular block after closure of an atrial septal defect with a gore septal occluder (GSO™).

Authors:  Sven Dittrich; Matthias Sigler; Helga Priessmann
Journal:  Catheter Cardiovasc Interv       Date:  2015-09-10       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.